Zim Laboratories Limited has informed the Exchange about Investor Presentation
ZIMLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Zim Laboratories reported weak Q1 FY26 results, with Total Operating Income falling 12.3% year-on-year to ₹718 Mn from ₹818 Mn, primarily due to geopolitical supply disruptions in the Middle East and Bangladesh. EBITDA dropped 36.7% to ₹57 Mn, with margins contracting sharply to 7.9% from 11% (a 310 basis point decline), and the company slipped into a loss with negative PAT of ₹19 Mn versus a profit of ₹9 Mn a year ago. On the positive side, the India business grew 30.2% to ₹100 Mn, dossier licensing milestone payments jumped to ₹45 Mn (from just ₹4 Mn last year), and 1 NIP filing in EU along with 4 NIP and 10 ODS filings in other markets were completed. The company also received 2 Marketing Authorizations in Australia and onboarded a full BD team covering Africa, CIS, LatAm, MENA, and SE Asia. R&D spending remained strong at ₹79 Mn (11% of operating income), and the NIP and OTF product pipelines across EU/UK were disclosed across all stages from formulation development to commercial supplies.
Short-term pressure on the stock is likely given the sharp decline in revenue, EBITDA, and a swing into losses, but the licensing milestone inflows, India growth, and visible product pipeline provide some support for a longer-term recovery story. Shareholders should watch for resolution of MENA supply issues and progress on the NIP/OTF pipeline as key catalysts.